Cardinal Health Inc Stock Price, News & Analysis

Cardinal Health (NYSE: CAH) has announced it will release its fourth-quarter and fiscal year 2025 financial results on August 12, 2025, before the NYSE market opening. The company will host a webcast discussion of the results at 8:30 a.m. Eastern.

Investors can access the webcast and accompanying slide presentation through Cardinal Health's Investor Relations page without requiring an access code. The presentation materials and webcast replay will remain available on the website for 12 months.

Cardinal Health (NYSE: CAH) has launched the Cardinal Health™ One Voice Initiative, a new program designed to provide financial support to state pharmacy associations to enhance independent pharmacists' advocacy efforts. The initiative aims to strengthen pharmacists' relationships with government officials and increase their influence in healthcare policy discussions.

Led by Brad Cochran, EVP of Pharmaceutical and Specialty Distribution, and Michelle Britt, SVP of Retail Independent Sales, the program will make financial contributions to state pharmacy associations, with future support expanding based on advocacy opportunities. The initiative emphasizes the importance of pharmacists sharing their firsthand experiences with lawmakers to drive meaningful healthcare policy changes.

Cardinal Health (CAH) announced updated financial guidance and strategic plans at its Investor Day. The company raised its FY25 non-GAAP EPS guidance to $8.15-$8.20 and provided preliminary FY26 EPS guidance of $9.10-$9.30, representing 13% growth. CAH raised long-term profit growth targets for its Pharmaceutical and Specialty Solutions segment to 5-7% and Other segment to ~10%. The company expects to generate at least $10B in adjusted free cash flow over the next three years and increased its baseline share repurchase to $750M annually. Strategic initiatives include launching The Specialty Alliance MSO platform, expanding Biopharma Solutions, investing in distribution infrastructure, and continuing the GMPD Improvement Plan. The company also plans significant investments in Nuclear and Precision Health Solutions and at-Home Solutions expansion.

Citius Oncology (CTOR), a subsidiary of Citius Pharmaceuticals (CTXR), has secured a distribution services agreement with Cardinal Health (CAH) for LYMPHIR, their FDA-approved immunotherapy treatment for relapsed or refractory cutaneous T-cell lymphoma (CTCL) in adults. The partnership positions Cardinal Health as an authorized distributor of record, leveraging their established pharmaceutical distribution network to facilitate LYMPHIR's upcoming U.S. commercial launch. This strategic agreement aims to ensure efficient and reliable delivery of LYMPHIR to healthcare providers and patients, marking a significant milestone in Citius Oncology's launch preparation strategy.

Cardinal Health (NYSE: CAH) has launched the Kendall DL™ Multi System in the U.S., a new medical device that enables continuous monitoring of cardiac activity, blood oxygen level, and temperature through a single connection point. This single-patient use monitoring system features innovative cable management and is designed to accompany patients throughout their hospital stay. The system's proprietary design reduces false alarms and motion-related artifacts in ECG tracings, while its single-use nature helps minimize cross-contamination risks. The device incorporates clinically proven technology to enhance patient care efficiency and can be reprocessed through Cardinal Health, potentially improving healthcare providers' financial performance.

Cardinal Health (NYSE: CAH) has released its 2025 Advanced Therapies Report, providing comprehensive insights into the cell and gene therapy (CGT) industry. The report, based on a survey of over 100 healthcare providers, reveals that the advanced therapy industry is projected to have over 200 therapies approved and treat more than 100,000 U.S. patients by 2030.

Key findings highlight significant challenges in CGT adoption, with 56% of respondents citing financial constraints and 54% pointing to inadequate reimbursement as major barriers. The report emphasizes the need for improved collaboration across industry stakeholders, with 69% of respondents supporting strategic initiatives between payers and manufacturers. Additionally, 64% identified insufficient social support as the primary reason patients don't receive needed CGT treatments.

Cardinal Health (NYSE: CAH) has announced a dividend increase, with the new quarterly dividend set at $0.5107 per share. The dividend will be paid on July 15, 2025, to shareholders who are on record as of July 1, 2025. The payment will be made from the company's capital surplus.

Cardinal Health (NYSE: CAH) reported strong Q3 FY25 results with flat revenue at $54.9 billion, but showing 19% growth excluding a customer contract expiration. GAAP operating earnings rose to $730 million with EPS of $2.10, while non-GAAP operating earnings increased 21% to $807 million with EPS of $2.35. The company demonstrated growth across all operating segments, with Pharmaceutical and Specialty Solutions profit up 14% to $662 million, Global Medical Products and Distribution profit up 77% to $39 million, and Other segment profit rising 22% to $134 million. Based on strong performance, Cardinal Health raised its FY25 non-GAAP EPS guidance to $8.05-$8.15 from $7.85-$8.00 and anticipates double-digit non-GAAP EPS growth in FY26.

Cardinal Health (NYSE: CAH) has announced it will release its third-quarter financial results for fiscal year 2025 on May 1, 2025, before the New York Stock Exchange opens. The company will host a webcast discussion of the results at 8:30 a.m. Eastern.

Investors can access the webcast and accompanying slide presentation through Cardinal Health's Investor Relations page without requiring an access code. The presentation materials and webcast replay will remain available on the company's Investor Relations page for 12 months following the event.